BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

...the transcription factor ATOH1. Novartis gained worldwide rights to the gene therapy in 2010 from GenVec Inc....
...Koch, Executive Editor; Winnie Pong, Associate Editor, Data & Analytics Cord Blood Registry Otonomy Inc. Pipeline Therapeutics Inc. Novartis AG GenVec Inc. Frequency...
BioCentury | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

...gene, in Phase I/II testing. Novartis gained exclusive, worldwide rights to CGF166 in 2010 from GenVec Inc....
BioCentury | Apr 13, 2018
Company News

Novartis to acquire AveXis for $8.7B

...CPK850 to treat retinitis pigmentosa. Novartis gained exclusive, worldwide rights to CGF166 in 2010 from GenVec Inc....
BioCentury | Apr 9, 2018
Company News

Novartis to acquire AveXis for $8.7B

...CPK850 to treat retinitis pigmentosa. Novartis gained exclusive, worldwide rights to CGF166 in 2010 from GenVec Inc....
BioCentury | Jun 2, 2017
Product Development

Ears wide open

...advanced therapeutic in this area is CGF166 , a gene therapy from Novartis AG and GenVec Inc....
...program in the clinic is CGF166, a gene therapy from Novartis AG (NYSE:NVS; SIX:NOVN) and GenVec Inc....
...BN201 and BN119 for inner ear disorders and anticipates making a decision by 3Q17; (B) GenVec Inc....
BioCentury | Apr 6, 2017
Distillery Techniques

Biomarkers

...CSP sequence of P. falciparum combined with the AS01 adjuvant, in registration to prevent malaria. GenVec Inc....
BioCentury | Feb 9, 2017
Translation in Brief

Delivering audio

...the clinic for hearing loss. One gene therapy, CGF166 from Novartis AG (NYSE:NVS; SIX:NOVN) and GenVec Inc....
BioCentury | Jan 27, 2017
Company News

GenVec, Intrexon deal

...stock deal. GenVec shareholders will receive 0.297 Intrexon shares per GenVec share, or $6.56 per GenVec...
...2016. The price is a 44% premium to GenVec's close of $4.54 on Jan. 23. GenVec...
...Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland). In 2010, GenVec granted Novartis exclusive, worldwide rights to GenVec's...
BioCentury | Jan 20, 2017
Company News

GenVec, Washington University deal

...university for IP and technology related to gene editing and pulmonary endothelial cell targeting technology. GenVec...
...in St. Louis , St. Louis, Mo. GenVec Inc. (NASDAQ:GNVC), Gaithersburg, Md. Business: Hematology, Gene/Cell therapy Shannon Lehnbeuter GenVec Inc. Washington...
BioCentury | Jan 11, 2017
Product R&D

Now hear this

...normal hearing. Several companies have been exploring regenerative medicine and gene therapy to restore hearing. GenVec Inc....
...details about its financing or investors. Companies and Institutions Mentioned Frequency Therapeutics Inc., Cambridge, Mass. GenVec Inc....
Items per page:
1 - 10 of 357
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

...the transcription factor ATOH1. Novartis gained worldwide rights to the gene therapy in 2010 from GenVec Inc....
...Koch, Executive Editor; Winnie Pong, Associate Editor, Data & Analytics Cord Blood Registry Otonomy Inc. Pipeline Therapeutics Inc. Novartis AG GenVec Inc. Frequency...
BioCentury | Dec 14, 2018
Product R&D

Gene therapy’s make or buy choice

...gene, in Phase I/II testing. Novartis gained exclusive, worldwide rights to CGF166 in 2010 from GenVec Inc....
BioCentury | Apr 13, 2018
Company News

Novartis to acquire AveXis for $8.7B

...CPK850 to treat retinitis pigmentosa. Novartis gained exclusive, worldwide rights to CGF166 in 2010 from GenVec Inc....
BioCentury | Apr 9, 2018
Company News

Novartis to acquire AveXis for $8.7B

...CPK850 to treat retinitis pigmentosa. Novartis gained exclusive, worldwide rights to CGF166 in 2010 from GenVec Inc....
BioCentury | Jun 2, 2017
Product Development

Ears wide open

...advanced therapeutic in this area is CGF166 , a gene therapy from Novartis AG and GenVec Inc....
...program in the clinic is CGF166, a gene therapy from Novartis AG (NYSE:NVS; SIX:NOVN) and GenVec Inc....
...BN201 and BN119 for inner ear disorders and anticipates making a decision by 3Q17; (B) GenVec Inc....
BioCentury | Apr 6, 2017
Distillery Techniques

Biomarkers

...CSP sequence of P. falciparum combined with the AS01 adjuvant, in registration to prevent malaria. GenVec Inc....
BioCentury | Feb 9, 2017
Translation in Brief

Delivering audio

...the clinic for hearing loss. One gene therapy, CGF166 from Novartis AG (NYSE:NVS; SIX:NOVN) and GenVec Inc....
BioCentury | Jan 27, 2017
Company News

GenVec, Intrexon deal

...stock deal. GenVec shareholders will receive 0.297 Intrexon shares per GenVec share, or $6.56 per GenVec...
...2016. The price is a 44% premium to GenVec's close of $4.54 on Jan. 23. GenVec...
...Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland). In 2010, GenVec granted Novartis exclusive, worldwide rights to GenVec's...
BioCentury | Jan 20, 2017
Company News

GenVec, Washington University deal

...university for IP and technology related to gene editing and pulmonary endothelial cell targeting technology. GenVec...
...in St. Louis , St. Louis, Mo. GenVec Inc. (NASDAQ:GNVC), Gaithersburg, Md. Business: Hematology, Gene/Cell therapy Shannon Lehnbeuter GenVec Inc. Washington...
BioCentury | Jan 11, 2017
Product R&D

Now hear this

...normal hearing. Several companies have been exploring regenerative medicine and gene therapy to restore hearing. GenVec Inc....
...details about its financing or investors. Companies and Institutions Mentioned Frequency Therapeutics Inc., Cambridge, Mass. GenVec Inc....
Items per page:
1 - 10 of 357